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Abstract
Change of DNA cytosine methylation (5mC) is an early event in the development of cancer, and the recent discovery
of a 5-hydroxymethylated form (5hmC) of cytosine suggests a regulatory epigenetic role that might be different
from 5-methylcytosine. Here, we aimed at elucidating the role of 5hmC in breast cancer. To interrogate the 5hmC
levels of the leucine zipper, putative tumor suppressor 1 (LZTS1) gene in detail, we analyzed 75 primary breast cancer
tissue samples from initial diagnosis and 12 normal breast tissue samples derived from healthy persons. Samples
were subjected to 5hmC glucosyltransferase treatment followed by restriction digestion and segment-specific
amplification of 11 polymerase chain reaction products. Nine of the 11 5′LZTS1 fragments showed significantly lower
(fold change of 1.61-6.01, P < .05) 5hmC content in primary breast cancer tissue compared to normal breast tissue
samples. No significant differences were observed for 5mC DNA methylation. Furthermore, both LZTS1 and TET1
mRNA expressions were significantly reduced in tumor samples (n= 75, P< .001, Student’s t test), which correlated
significantly with 5hmC levels in samples. 5hmC levels in breast cancer tissues were associated with unfavorable
histopathologic parameters such as lymph node involvement (P < .05, Student’s t test). A decrease of 5hmC levels
of LZTS1, a classic tumor suppressor gene known to influence metastasis in breast cancer progression, is correlated
to down-regulation of LZTS1mRNA expression in breast cancer andmight epigenetically enhance carcinogenesis. The
study provides support for the novel hypothesis that suggests a strong influence of 5hmC on mRNA expression.
Finally, one may also consider 5hmC as a new biomarker.
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Introduction
Cytosine methylation is a well-studied epigenetic mechanism, which
is essential for silencing of repetitive elements, X-chromosome inac-
tivation, or imprinting and is also involved in gene repression and
chromatin remodeling [1] through recruitment of specific factors [2].
Changes in DNA methylation can be detected early during tumori-
genesis [3], and recent data have allowed for tumor classification based
on genome-wide DNA methylation signatures of different cancers [4].
Methylated cytosines can be subjected to hydroxymethylation (5hmC)
by ten eleven translocation (TET) enzymes, which was discovered in
mammalian genomes in 2009 by Kriaucionis and Heintz [5]. How-
ever, the function and underlying mechanisms of 5hmC DNA modi-
fication have not yet been fully elucidated and it is still unclear whether
5hmC serves solely as a precondition for DNA demethylation or has
a regulatory role by itself [6]. Classic bisulfite deamination–based
sequence analysis cannot distinguish 5hmC from 5mC [7], but recent
advances have made it possible to determine 5hmC-modified sequences
by introducing an oxidative step into the DNA bisulfite conversion
procedure [8]. Most studies have relied on a global antibody-based
determination of 5hmC levels in different cell and tissue types [9],
which was correlated with increased mRNA expression of target genes
[10] and increased expression of TET proteins [11]. 5hmC levels have
been analyzed in different tissues, and high levels of this modification
were found in brain, kidney, or liver [9,10,12]. Loss of 5hmC has been
observed in different cancers [13] and linked to decreased TET expres-
sion and mutations in isocitrate dehydrogenase 1 (IDH1 and IDH2)
[14]. In mouse embryonic stem cells, 5hmC was found to be associated
with active promoters and correlated with increased expression, and si-
lencing of TET1 and TET2 resulted in increased 5mC and decreased
expression of a group of genes including pluripotency factors [15]. A
recently published report suggests that 5hmC is lost, resulting from a
replication-dependent passive process [16].
Leucine zipper, putative tumor suppressor 1 (LZTS1) is a tumor sup-
pressor, which was found repressed in various cancers such as breast
carcinoma [17], squamous cell carcinoma [18], uveal melanoma
[19], and bladder cancer [20]. Furthermore, the reduced amounts of
mRNA in breast cancer could be connected to high histologic grade
lymph node metastasis and poor prognosis in breast cancer [21]. Loss
of LZTS1 could, until now, not be explained by genetic factors like
mutations or loss of heterozygosity (LOH) [20]. However, epigenetic
silencing of LZTS1 by DNA methylation was described in breast can-
cer [17,21] and malignant mesothelioma of the lung where the methyla-
tion status correlated with patient’s lymph node involvement [22].
In this study, we aimed at exploring the feasibility of 5hmC as a bio-
marker in breast cancer by application of a targeted microarray [23]
interrogating 323 loci. We detected aberrant 5-hydroxymethylation
as well as unaffected methylation levels of LZTS1 of DNA from breast
cancer samples compared to normal breast tissue, which correlated
with the mRNA expression of the LZTS1 gene and TET1. Further,
the variances in 5hmC within the patients with breast cancer could
be connected to patients’ nodal involvement.
Patients and Methods
Samples and Patients
A total of 75 fresh frozen invasive breast cancer tissue samples derived
from patients with breast cancer and 12 samples containing normal breast
tissue were collected at the Department of Obstetrics and Gynecology,
Medical University of Vienna (Vienna, Austria) between 1990 and
1999 (Table 1). Twenty-six patients with breast cancer (34%) did not
have involved lymph nodes at the time of surgery, whereas 47 patients
(52%) had one or more lymph nodes involved. More detailed informa-
tion on patient characteristics is given in Table 2. An assay control female
blood was obtained from the Austrian Red Cross Blood Center. The
Blood Center provided anonymized samples after the testing was success-
fully completed in accordance with the institute’s guidelines. The study
was approved by the ethics committee of the Medical University of
Vienna and was carried out in compliance with the Helsinki Declaration.
Nucleic Acid Extraction
Approximately 15 mg of breast tissue was applied per sample
for tissue lysis. Lysis was performed in Lysis Matrix A tubes (MP
Biomedicals, Eschwege, Germany) combining the tissue and pre-
chilled RLT plus buffer (Qiagen, Hilden, Germany) including
2-mercaptoethanol (Sigma, St Louis, MO). To achieve tissue extrac-
tion, a repeated bead whirling procedure was applied on a Fast Prep
24 (MP Biomedicals) at a speed setting of 5.5 for 30 seconds, twice
per sample. The lysate was subsequently centrifuged at 13,000 rpm
for 3 minutes to remove cell debris. The resulting 600 μl of cell lysate
was applied to a Qiagen All Prep procedure, which was performed
according to the manufacturer’s instructions. DNA concentrations
were determined through absorbance measurements. The quality and
quantity of RNA were appointed with absorbance measurement and
Agilent RNA 6000 Nano microfluidic chip.
Analyses of 5-Hydroxymethylcytosine
We applied a method that enables specific screening of 5hmC in
DNA samples with quantitative polymerase chain reaction (qPCR) or
Table 1. Clinical Features of Breast Cancer Patients.
Characteristics Patients (n = 75)
Nodal involvement
LN0 n = 26 (34%)
LN1 n = 39 (52%)
LN2 n = 8 (10%)
NA n = 2 (3%)
Tumor metastasis
No n = 29 (39%)
Yes n = 46 (61%)
Histologic type
Invasive lobular n = 13 (17%)
Invasive ductal n = 56 (74%)
Other n = 4 (5%)
NA n = 2 (3%)
Progesterone receptor status
Negative n = 47 (62%)
Positive n = 28 (37%)
Estrogen receptor status
Negative n = 30 (40%)
Positive n = 45 (60%)
Tumor grade
1 + 2 n = 35 (47%)
3 + 4 n = 35 (47%)
NA n = 5 (6%)
Tumor size
1 n = 19 (25%)
2 n = 45 (60%)
3 + 4 n = 9 (12%)
NA n = 2 (3%)
NA indicates patients, where the specific annotation was not available.
Characteristics reflect the analyzed subsets within the 75 patients with breast cancer. “Patients”
indicate the number of patients within each clinical subset, also given in a percentage. The clinical
annotation was not available for all 75 tested patients with cancer.
716 Reduction of LZTS1 5-Hydroxymethylation in Cancer Wielscher et al. Translational Oncology Vol. 6, No. 6, 2013
a targeted microarray. The principle of this approach is based on the
selective glucosylation of 5hmC with T4-β-glucosyltransferase, which
transfers a glucose moiety from uridine diphosphoglucose onto 5hmC,
thus modifying it to glucosyl-5′-hydroxymethylcytosine (glu-5hmC),
and the inability of glucosyl-sensitive restriction enzymes (GSREs) like
MspI to digest glu-5hmC DNA. MspI is not sensitive to methylated
or hydroxymethylated DNA and therefore enables a differentiation
between glucosylated (i.e., hydroxymethylated) DNA and unmodified
or methylated DNA. The initial screening for 5hmC markers was
performed on a targeted microarray analyzing 323 genetic loci for their
5hmC status (Table W1).
Glucosylation of 5-Hydroxymethylcytosine
Glucosylation of 5hmC was performed using the Quest 5hmC
Detection Kit (Zymo Research, Irvine, CA), according to manufacturer’s
instructions. Five hundred nanograms of genomic DNA from patient
samples, standardized controls, and blood was applied to the Quest
5hmC Detection Kit. To distinguish between 5-hydroxymethylated
DNA and methylated or unmethylated DNA, each reaction was split
into two reactions containing the 5hmC glucosyltransferase enzyme or
no enzyme, respectively. The reactions were incubated for 2 hours at
37°C in a total volume of 50 μl.
Glucosylation-Dependent Restriction Digestion (GSRE)
To detect differences between 5hmC-glucosylated DNA and mock-
treated DNA, a restriction digestion with MspI endonuclease was
performed. Thirty units of MspI were applied to each reaction and
incubated at 37°C overnight. Each reaction was heat inactivated at
65°C for 20 minutes and subsequently purified with DNA Clean &
Concentrator (Zymo Research). Performance of GSREwas tested using
control DNA and a concordant primer (Figure W1).
Analyses of Methylcytosine
Similar to GSRE-dependent analysis of 5hmC content, methyla-
tion levels were assessed using the MspI isoschizomer HpaII, which
is blocked by methylated cytosines. Two hundred nanograms of
genomic DNA was subjected to methyl-sensitive restriction digestion
(MSRE) in a reaction volume of 30 μl using 0.2 unitsHpaII (Fermentas,
Burlington, CA) per μl. The reaction was incubated at 37°C for
16 hours followed by 20 minutes at 65°C to inactivate the enzyme.
Aliquots (2 μl) of reaction were subjected to qPCR. Methylation-specific
qPCR was performed on all LZTS1 fragments and the internal control
(Table W2).
Quantitative Polymerase Chain Reaction
We performed qPCRs to measure the difference between hydroxy-
methylated DNA, which was glucosylated and therefore the restric-
tion enzyme was blocked, and non-hydroxymethylated DNA (where
the restriction enzyme cuts both positive and negative reactions of the
DNA samples without glucosyltransferase enzyme). The qPCR setup,
LC480 instrument settings, and cycle threshold (C t) values were
published previously [24]. The primer for genomic DNA amplifica-
tion and that for reverse transcription (RT)–qPCR were optimized
and pretested according to the minimum information for publication
of quantitative real-time PCR experiments (MIQE) guidelines. PCR
annealing temperatures and primer sequences are given in Table W2.
Primer Optimization
To exclude experimental bias in the analyzed data sets, primers were
tested before use as suggested in MIQE guidelines by Bustin et al. [25].
A serial dilution ranging from 50 ng per qPCR reaction to 0.05 ng
per qPCR was analyzed with every primer pair. This enabled us to
create a five-point standard curve for every primer. The PCR effi-
ciency, slope, intercepting point with y-axis, and correlation coefficient
were then calculated (Table W2).
cDNA Generation and RT-PCR
RNA samples showing an RNA integrity number greater than six
were used for cDNA synthesis with 100 ng of total RNA (SuperScript
VILO; Invitrogen, Carlsbad, CA). Before qPCR, the cDNA was diluted
1:3 where 2 μl of cDNA was used for each RT-qPCR. The PCR was
performed as described above with an annealing temperature of 60°C.
Data Analysis
For the detection on the targeted microarray of gene loci with a
significant difference between glucosylated (corresponding to gene loci
with 5hmC) and unglucosylated (no 5hmC present) samples, the me-
dian signal intensity of the microarray data of each spot was log2 trans-
formed and statistically analyzed with BRB array tools [26]. On the
basis of the P value (by Student’s t test) and the mean of the log2 trans-
formed median intensities of the samples, the markers were selected.
To exclude the influence of different DNA concentrations on qPCR,
all qPCR results were normalized to a control fragment or housekeeping
gene (Table W2), yielding ΔC t values. Differential hydroxymethylated
DNA fragments are displayed as mean log2 fold change + SD. Fragments
with higher C t values for glucosylated samples than untreated controls
were scored as 0. Statistical tests were performed in GraphPad Prism5
(GraphPad Software Inc, San Diego, CA). Calculation of the log2 fold
change was based on ΔΔC t differences between the negative reactions
of each sample and the positive (glucosylated) sample (Figure 1). These
ΔC t values were then compared between the sample groups (i.e., sub-
traction ofΔC t values of normal control samples fromΔC t values derived
from cancerous tissue) yielding a “fold change value.” For calculation
of methylation levels, ΔΔC t values were calculated in the same way as
for 5hmC levels. Subsequently, the ΔΔC t values reflecting the 5hmC
levels were subtracted from the ΔΔC t values gained from methylation
analysis, to yieldmethylation levels that reflect solelymethylation changes
and not a mixture of methylation changes and 5hmC changes.
Results
Identification of LZTS1 as a Target for Altered
5-Hydroxymethylation in Primary Tumors of
Patients with Breast Cancer
The method for 5hmC detection of DNA samples performed in this
study relies on in vitro glucosylation of 5hmC and subsequent restric-
tion digestion using MspI, which is blocked by glucosylated cytosine
in 5′-C^CGG-3′, whereas unmodified or methylated cytosine can be
digested. We initially established the assay to detect 5hmC using qPCR
comparing glucosylated and unglucosylated control DNA (FigureW1).
To detect differences in 5hmC levels in peripheral blood mononuclear
cells of healthy donors and breast cancer tissues, we used a targeted
microarray containing 323 cancer-associated genetic loci. Except for
three candidate genes, the 5hmC levels were generally low and com-
parable between breast cancer tissues and peripheral blood mono-
nuclear cells (Table W1). We were able to validate higher 5hmC
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levels in breast tissue than in peripheral blood for the LZTS1 gene
(Figure W2).
Next, we aimed at analyzing 5hmC levels of the LZTS1 gene in
more detail in a larger patient cohort including the screening set
samples. PCR amplicons (A-K) were designed for analyzing a region
from −98 to +2567 relative to the transcription start site of the LZTS1
gene. We performed qPCR analyses of 75 breast cancer samples and
12 normal control breast samples (Figure 1). We used the ΔΔC t values
(glucosylated − unglucosylated) to assess the 5hmC levels in the dif-
ferent samples with significant values for breast cancer and normal
tissues for all PCR fragments tested (P < .01). A mean ΔΔC t of
3.5 ± 1.4 was calculated for normal breast tissue samples and a mean
ΔΔC t of 1.95 ± 0.95 for cancerous samples.
Furthermore, our analyses demonstrated a significant decrease of
5hmC levels in fragments A to I in breast cancer versus healthy control
breast tissues with a mean difference (i.e., log2 fold change) of 1.23 ±
0.54 (Figure 1B). The log2 fold changes ranged from 2.6 ± 0.57 (i.e.,
fold change of 6.01) for fragment C to 0.7 ± 0.3 (i.e., fold change of
1.72) for fragment B. All numerical fold change values as well as area
under curve (AUC) values derived from receiver operating characteris-
tic (ROC)-curve analysis of fragments distinguishing between normal
tissue and breast cancer tissue are given in Table 2.
Figure 1. (A) ΔΔC t values of qPCR-tested fragments of the LZTS1 locus on all sample groups. ΔC t methodology was applied to minimize
the experimental bias and varying DNA concentrations. ΔΔC t values were obtained by qPCR, and the negative reaction of each sample was
then subtracted from the positive (glucosylated) sample and plotted as the mean difference of each sample group. Fragments A to K reflect
the different qPCR-tested regions of the LZTS1 locus. BRCA, breast cancer patients; CONTR, healthy controls were derived from healthy
breast tissue; FRAG, fragment. (B) Chromosomal position of LZTS1 including MspI cut sites is given. CpG density plot indicates the
percentage of CpG in genomic DNA of the tested region. Blue drawing indicates LZTS1mRNA including RefSeq.; fragments A to K reflect
the different qPCR-tested regions of the LZTS1 locus, which were plotted according to their chromosomal positions. Asterisks indicate
significance levels of fragments distinguishing healthy controls and patients with breast cancer. *P< .05, **P< .01, ***P< .001; log2 fold
changes were calculated between healthy controls and patients with breast cancer on the basis of ΔΔC t values.
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To get deeper insight into the epigenetic regulation of LZTS1,
the 5mC levels within this region were also assessed, testing the
same PCR fragments (A-J) as for 5hmC determination after MSRE
digest with the methylation-sensitive MspI isoschizomer HpaII. As
depicted in Figure 2, comparable low levels of methylation were
observed after subtraction of 5-hydroxymethylated DNA from the
methylated fraction in the respective regions. Fold changes ranged
from 0.01 for fragment E to a methylation increase in patients with
cancer of 2.1 for fragment C.
Altered LZTS1 and TET1 mRNA Expression in Primary
Tumors of Patients with Breast Cancer
High levels of 5hmC were correlated with active transcription in
genome-wide approaches before [10,15]. Thus, we analyzed the
mRNA expression levels of LZTS1 in normal breast versus breast
tumor samples (Figure 3A). Our data demonstrate a significant down-
regulation (P < .0001, Student’s t test) of LZTS1 mRNA expression
in breast cancer samples, which correlated with decreased levels of
5hmC across the LZTS1 locus. Furthermore, we observed a significant
reduction of TET1 expression in cancerous breast tissue, showing a
difference in ΔC t values of 2.8 (fold change = 6.96; Figure 3A). A
sample-wise correlation between gene expression and 5hmC levels of
defined fragments (C-I) indicated a link between 5hmC and LZTS1
expression as well as 5hmC levels and TET1 expression (Spearman
correlation of P < .01; Figure 3B). These data suggest a disturbed
5hmC conversion of 5mC in tumors, which might result in decreased
expression of target genes such as LZTS1.
5hmC Levels of LZTS1 in Primary Tumors with Respect to
Breast Cancer Pathology
In a next step, we raised the question of whether this decreased level
of 5hmC may be linked to any clinical characteristics of the tested
patients. The comparison of patients with no metastasis (n = 29) and
patients with breast cancer with distant metastases (n = 46) did not
yield any significant correlation to altered 5hmC levels in tissues of
primary tumors of the tested patients. When patients were grouped
according to nodal involvement (LN0, LN1, and LN2), the 5hmC
levels of six fragments were significantly associated with nodal in-
volvement (five of six presenting a decrease in LN2; Figure W3 and
Table 2). Interestingly, a robust decrease in 5hmC levels was apparent
between stages LN1 and LN2 (1.37 ± 0.47; fold change = 2.58),
whereas solely for one fragment significant changes between LN0
and LN1 were observed.
Discussion
5-Hydroxymethylation of cytosines is a dynamic process, which makes
5hmC an appropriate target for biomarker development in the field
of cancer diagnostics and prognostics. Recently published data relying
on sequencing-based methods show a decrease of 5hmC in neoplastic
tissue for both a global reduction and a decrease in the promoter re-
gion of genes [27]. Immunohistochemical analysis further indicated a
global decrease of 5hmC in many cancerous tissues such as lung and
brain [28], and by the application of immunohistochemical methods
and tiling microarrays, Nestor et al. [12] showed that both global
5hmC content and the 5hmC content of specific gene clusters are
strongly dependent on the tissue type, with highest levels in brain
tissue and very low levels in blood cells. These observations might
explain that solely 3 regions of 323 tested showed detectable levels of
5hmC in patients with breast cancer and none could be identified in
the blood samples tested in our study (Table W1). LZTS1, which we
validated by qPCR, showed a reduced level of 5hmC in DNA from
primary tumors of patients with breast cancer versus normal breast
tissue from healthy individuals. Recently published data concerning
5hmC levels in patients with melanoma are in line with our finding
of reduced 5hmC levels in malign neoplasms [27]. The authors further
suggest that loss of 5hmC serves as a hallmark in malignant transfor-
mation and 5hmC might be taken into consideration as a biomarker.
However, quantitative determination of 5hmC content for a specific
locus is still rare [12].
LZTS1 is a classic tumor suppressor gene, and its altered expres-
sion in tumor samples has been proven for many cancer types [17].
In this study, we show a correlation between decreased 5hmC levels
and lower mRNA expression for LZTS1, which is in coherence with
recent reports demonstrating a correlation between increased mRNA
expression and increased 5hmC levels in gene bodies [10,29]. Loss
of LZTS1 expression has been associated with tumor progression,
Figure 2. Methylation levels of LZTS1 locus; identical qPCR assays
(fragments A-K) as for 5hmC assessment were used. ΔC t method-
ology was applied to minimize the experimental bias and varying
DNA concentrations. ΔΔC t values were obtained by subtraction
of the negative untreated sample from the HpaII digested sample
values. To remove the effect of the 5-hydroxymethylation on the
data, the ΔΔC t value of the 5hmC levels of each fragment was
subsequently subtracted from the methylation values. Bars reflect
the mean difference of each sample group.
Table 2. LZTS1 5-Hydroxymethylation in Cancerous and Normal Breast Tissues.
Fragment BRCA versus CONTR LN0 versus LN1 LN1 versus LN2
FC P Value AUC FC P Value AUC FC P Value AUC
A −1.35 ** 0.75 −0.41 NS 1.12 NS
B −0.69 * 0.73 −0.34 NS 0.83 * 0.82
C −2.47 *** 0.87 −0.81 NS 1.88 ** 0.82
D −1.84 *** 0.83 −0.54 NS 1.12 * 0.72
E −1.61 *** 0.87 −0.39 NS 1.27 NS
F −0.88 * 0.7 −0.17 NS 1.58 ** 0.87
G −1.85 *** 0.84 −0.56 NS 1.45 ** 0.81
H −1.37 *** 0.82 −0.51 NS 1.02 NS
I −1.45 *** 0.83 −0.78 * 0.7 0.58 NS
J −0.32 NS 0 NS 0 NS
K 0 NS 0 NS 0 NS
P values and fold changes of qPCR-tested fragments of BRCA versus healthy controls and within
the clinical subgroups of patients with breast cancer. BRCA, breast cancer; LN, lymph node affection
as part of tumor grading; fragments A to K reflects the different qPCR-tested regions of the LZTS1
locus. Significance was determined by Student’s t test; NS, not significant; *P < .05, **P < .01, and
***P < .0001; FC indicates the log2 fold change; AUC refers to area under curve calculation (ROC
curve analysis) of all significant rated fragments.
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metastasis, and poor prognosis in mouse models and human can-
cer [30]. Although, we could not detect significant associations of
5hmC levels with metastasis status, we demonstrated a significant
correlation between 5hmC levels to nodal involvement, which might
represent a group of more progressed tumors.
The observed lower levels of 5hmC in the LZTS1 gene in breast
cancer samples might be due to lower levels of TET1 expression,
which is essential for the conversion of 5mC to 5hmC, and was also
described in other recently published reports [11,31]. The down-
regulation of TET family DNA hydroxylases and that of IDH2 [27],
which both are necessary to transfer an OH– group to methylated
cytosines, are the key players leading to the dynamic changes of
5hmC in neoplastic transformation [32] and during embryonic devel-
opment [33]. One might also speculate that reduced levels of TET1
might yield an accumulation of 5mC and repression of the underlying
gene, which is in line with reports demonstrating hypermethylation of
the LZTS1 promoter in breast cancer [17].
Regarding 5mC DNA methylation analysis performed in this
study, we did not find a sample-wise correlation between 5hmC and
5mC levels. If 5mC values were not corrected for hydroxymethylation
by subtraction, they mirrored the changes of the 5-hydroxymethylation
to a lower extent (Figure W4), a fact that is in line with DNA methyla-
tion data available from the ENCODE consortium [34,35], showing
lower DNA methylation levels of the LZTS1 promoter and gene
body in cell lines derived from a ductal carcinoma compared to nor-
mal breast tissue both in data sets generated by use of Illumina
450K bead arrays and reduced representation bisulfite sequencing by
Dr Richard Myers Lab and Dr Devin Absher Lab at the HudsonAlpha
Institute for Biotechnology.
After normalization of the 5mC data for the hmC effect (Figure 2),
no significant changes of 5mC levels were observed. Solely for frag-
ment C, where the highest portion of hydroxymethylation was ob-
served, a clear, but not significant, change of methylation in line
with lower hydroxymethylation was observed [36]. However, residual
Figure 3. (A) Decreased mRNA expression of LZTS1 and TET1 in patients with breast cancer and their correlation to 5hmC levels. Upper
panel reflects mRNA expression of LZTS1 and TET1. ΔC t method was applied on qPCR data followed by division to gain a straight-
forward illustration of expression direction. As housekeeping gene, the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was measured; ***P < .001. (B) Correlation between 5hmC levels given as ΔΔC t values and mRNA expression. The mRNA expression of
LZTS1was connected to 5hmC levels in a way that each sphere represents one patient sample. Fragments showing a significant Spearman
correlation (fragments C-I) were plotted; for correlation between TET1 mRNA expression and 5hmC levels, the same fragments showed a
significant Spearman correlation. Error bars indicate variance between 5hmC levels (i.e., ΔΔC t values) for each sample.
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fragments showed no or marginally changed methylation levels in
patients with breast cancer compared to normal controls.
In sum, this study shows quantitative locus-specific measures of
5hmC and 5mC levels in a clinical sample cohort, where the reduced
expressions of both the LZTS1 and TET1 genes are correlated with
decreased 5hmC levels in patients with breast cancer. Further, a
significant change in LTZS1 5hmC content was found in primary
breast cancer tissue from initial diagnosis dependent on their lymph
node involvement stage. Our detailed analysis of the LZTS1 hydro-
xymethylation status provides new insights into the dynamics of
5hmC levels in malignant neoplasms and may also provide new
impulses for the determination of the exact function of 5hmC.
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Supplementary Materials and Methods
Testing of Quest 5-hmC Detection Kit (Zymo Research)
Before experiments were performed on clinical sample materials,
the Quest 5-hmC Detection Kit was tested on test DNA included
in the kit and in vitro hydroxymethylated DNA of the BRCA1 locus.
For in vitro hydroxymethylation, a PCR was performed using a
primer pair (forward: gccccctgtccctttcccgggact; reverse: aaactgcga-
ctgcgcggcgtgag) for the BRCA1 locus. This PCR was performed by
adding hydroxymethylated cytosines (hydroxymethyl dCTP; Bioline,
Berlin-Brandenburg, Germany) to the reaction. Subsequently, we used
equal amounts of DNA as control reactions without any treatment and
as a reaction performed according to the manufacturer’s instructions.
We yielded a mean difference between negative reaction and positive
reaction, inclusive 5hmC glucosyltransferase enzyme of 3.06 ± 0.06
using the control DNA supplied by Zymo Research, and a mean
difference of 1.84 ± 0.18 of in vitro hydroxymethylated DNA.
Identification of LZTS1 on Targeted Microarray
DNA samples from breast cancer tissue (n = 6) and blood samples
from healthy patients (n = 6) were used to determine 5hmC levels of
323 regions on a targeted microarray. To this end, 500 ng of DNA
input of each sample was glucosylated with 5hmC glucosyltransferase
to glu-5hmC for 6 hours at 37°C and digested with the GSRE MspI,
according to the manual of the Quest 5-hmC Detection Kit (Zymo
Research). The control reaction of each sample was only treated with
MspI without prior glucosylation. The amplification products of the
multiplex PCR with 360 target DNA fragments from each sam-
ple were pooled in a 0.2-ml PCR tube and hybridized onto the
CpG-360 microarray for analysis of 5hmC in 323 gene loci and
5mC in all gene loci. Due to the fact that all samples were amplified
with biotinylated primers, the detection of the hybridized amplicons
on the microarray was performed with streptavidin Cy3 conjugate
(CALTAGLaboratories, San Diego, CA), which binds biotin with high
affinity. The Cy3 signals were scanned with GenePix 4000A (Axon In-
struments) at an excitation wavelength of 532 nm and an emission
wavelength of 560 nm at a photomultiplier tube setting of 800
PMT. The microarrays were analyzed and translated into data files
by the GenePix 4000A software. For the detection of gene loci with
a significant difference between glucosylated and unglucosylated sam-
ples and gene loci with 5mC, the median signal intensity of the micro-
array data of each spot was log2 transformed and statistically analyzed
with BRB array tools for Microsoft Excel [1].
On the basis of the P value (by Student’s t test) and the mean of
the log2 transformed median intensities of the samples, we selected
three gene loci with a significant difference between the glucosylated
and unglucosylated groups for detection of 5hmC markers.
As depicted in Table W1, the three genes show an altered 5hmC
breast cancer patients. All three markers were validated by qPCR,
where one gene (LZTS1) showed an altered level of 5hmC after
qPCR in the preliminary sample set. The described breast cancer
samples (Table W1) were then processed and analyzed again within
the main study.
qPCR Validation of LZTS1
Primer optimization. To exclude experimental bias in the analyzed
data sets, primers were tested before use as suggested in MIQE guide-
lines by Bustin et al. A serial dilution ranging from 50 ng per qPCR
reaction to 0.05 ng per qPCR was analyzed with every primer pair. This
enabled us to create a five-point standard curve for every primer. The
PCR efficiency, slope, intercepting point with y-axis, and the correlation
coefficient were then calculated.
Table W1. Microarray Results Leading to the Identification of Altered 5hmC Level of LZTS1.
Gene Mean Intensities in Glucosylated
Sample Group
Mean Intensities in Unglucosylated
Sample Group
P Value
LZTS1 410.57 112.38 .0148
SOCS1 200.02 68.91 .0369
TP53 3564.11 905.54 .0404
The absolute signal intensities and P values of three candidate genes for qPCR validation are given
in Table 1.
Figure W1.Quest 5-hmC Detection Kit testing using DNA supplied by Zymo Research and in vitro hydroxymethylated DNA of the BRCA1
PCR product. C t values, unnormalized raw data; MspI (gluc) indicates positive reaction, where 5-hmC glucosyltransferase enzyme was
added to the reaction; MspI indicates reactions with the same input DNA (in vitro hydroxymethylated) but without the enzyme.
Table W2. PCR Products plus Primer Sequences and PCR Efficiency.
PCR Product Target Left Primer Right Primer Tm Slope d R2 PCR Efficiency
LZTS1_frag_A DNA cccagtgaatgtttgttgaat tctgggcagtagagaaacaca 65 −3.20 26.55 0.997 105.20
LZTS1_frag_B DNA cttgctgccacagccttt ccggagatgaggctactgac 65 −3.80 29.30 0.996 83.38
LZTS1_frag_C DNA ggcttcgcagtacaagctg agtcctgggagaagccaaac 65 −4.26 35.41 0.981 71.58
LZTS1_frag_D DNA gcgtcagtagcctcatctcc tcttgaggtgggaggacttg 65 −3.95 30.65 0.992 79.20
LZTS1_frag_E DNA atgggcaagagcgaagact ctaaatccccgctggacagt 65 −3.34 26.77 0.997 99.28
LZTS1_frag_F DNA cagactcctcaaaaccagagc acttctgcttcagggggact 65 −4.01 35.35 0.992 77.68
LZTS1_frag_G DNA ctggaagcacagatgaagagg agggcagcaaatgagaagac 65 −3.46 27.38 0.999 94.43
LZTS1_frag_H DNA attcagtcctctgccccttg gccccttaatttgaaaagctg 65 −3.41 25.64 0.999 96.40
LZTS1_frag_I DNA caggagccatcctgcact gcttcagctcctgctcctt 65 −3.95 29.93 0.996 79.07
LZTS1_frag_J DNA caaggagcaggagctgaag gctgctggtgctgtgtgt 65 −3.61 27.17 0.999 89.22
LZTS1_frag_K DNA ctgcagcttcagcaggaga ctcgtaggacctgagcttgg 65 −4.24 35.11 0.961 72.16
control DNA gctctgcccatagatgcctttg tccctggttttgacctggggga 65 −3.48 29.29 0.998 93.97
LZTS1 mRNA gactgcttctctcattcctgc acaatgtgttgcccaaccaaag 60 −4.14 34.76 0.996 74.21
TET1 mRNA ccggcgcgagttggaaagtt aaggtttttggtcgctggccg 60 −3.81 32.52 0.994 82.86
GAPDH mRNA atcactgccacccagaagac atgaggtccaccaccctgtt 60 −3.63 30.04 0.993 88.41
“Target” indicates if primer is specific to mRNA of DNA; “Tm” reflects the annealing temperature that was applied to perform qPCR; “slope” represents slope of standard curve; d gives the intercept
point of the standard curve and the y-axis; R2 indicates correlation coefficient.
Figure W2. qPCR validation of LZTS1 on the discovery sample set
(previous section) shows changed 5hmC levels in cancer compared
to no change in 5hmC content in blood of healthy donors. Canc+
indicates positive reaction inclusive of glucosyltransferase enzyme;
canc− indicates negative reaction without the enzyme.
Figure W3. LZTS1 5-hydroxymethylation in cancerous breast tissue.
5-Hydroxymethylated fragments correlate to patient’s lymph node
affection. ΔC t method was applied to minimize the experimental
bias and varying DNA concentrations. ΔC t values were obtained
by qPCR. The negative reaction of each sample was then subtracted
from the positive (glucosylated) sample and plotted as the mean
difference of each sample group. Fragments A to I reflect the dif-
ferent qPCR-tested regions of the LZTS1 locus. LN0, patients with
no lymph node involvement detected (n = 26); LN1, patients with
lymph node affection of clinical grade 1 (n = 39); LN2, patients
with local lymph node affection of grade 2 (n=8); error bars indicate
the SEM; *P < .05 and **P < .01.
Figure W4. Methylation levels of LZTS1 locus; identical qPCR assays (fragments A-K) such as for 5hmC assessment were used. ΔC t
methodology was applied to minimize the experimental bias and varying DNA concentrations. ΔΔC t values were obtained by subtraction
of the negative untreated sample from the HpaII digested sample values. The effect of 5hmC was not considered. The plot reflects a
combination of 5hmC and 5mC of the LZTS1 locus.
